# Parry J Guilford

List of Publications by Year
in descending order



| 78 | 9,748 | 71061 41 | 74108 75 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 80 | 80 | 80 | 8691 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | E-cadherin germline mutations in familial gastric cancer. Nature, 1998, 392, 402-405. | 13.7 | 1,542 |
| 2 | Defective myosin VIIA gene responsible for Usher syndrome type IB. Nature, 1995, 374, 60-61. | 13.7 | 1,101 |
| 3 | Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology, 2001, 121, 1348-1353. | 0.6 | 579 |
| 4 | Hereditary Diffuse Gastric Cancer Syndrome. JAMA Oncology, 2015, 1, 23. | 3.4 | 540 |
| 5 | Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. Journal of Medical Genetics, 2010, 47, 436-444. | 1.5 | 495 |
| 6 | Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germlineCDH1mutation carriers. Journal of Medical Genetics, 2015, 52, 361-374. | 1.5 | 479 |
| 7 | Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nature Genetics, 2000, 26, 16-17. | 9.4 | 420 |
| 8 | Early events in cell adhesion and polarity during epithelial-mesenchymal transition. Journal of Cell Science, 2012, 125, 4417-4422. | 1.2 | 286 |
| 9 | A nonâ€“syndromic form of neurosensory, recessive deafness maps to the pericentromeric region of chromosome 13q. Nature Genetics, 1994, 6, 24-28. | 9.4 | 262 |
| 10 | E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Human Mutation, 1999, 14, 249-255. | 1.1 | 247 |
| 11 | Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncology, The, 2020, 21, e386-e397. | 5.1 | 237 |
| 12 | Triple gene block proteins of white clover mosaic potexvirus are required for transport. Virology, 1991, 183, 695-702. | 1.1 | 200 |
| 13 | The Y Deletion gr/gr and Susceptibility to Testicular Germ Cell Tumor. American Journal of Human Genetics, 2005, 77, 1034-1043. | 2.6 | 197 |
| 14 | Hereditary Diffuse Gastric Cancer: Diagnosis and Management. Clinical Gastroenterology and Hepatology, 2006, 4, 262-275. | 2.4 | 163 |
| 15 | E-Cadherin Deficiency Initiates Gastric Signet-Ring Cell Carcinoma in Mice and Man. Cancer Research, 2009, 69, 2050-2056. | 0.4 | 147 |
| 16 | Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer, 2010, 13, 1-10. | 2.7 | 143 |
| 17 | Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Human Molecular Genetics, 2006, 15, 443-451. | 1.4 | 138 |
| 18 | A human gene responsible for neurosensory, non-syndromic recessive deafness is a candidate homologue of the mouse sh-1 gene. Human Molecular Genetics, 1994, 3, 989-993. | 1.4 | 134 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Germline E-cadherin gene mutations. Cancer, 2001, 92, 181-187. | 2.0 | 131 |
| 20 | A Multigene Urine Test for the Detection and Stratification of Bladder Cancer in Patients Presenting with Hematuria. Journal of Urology, 2012, 188, 741-747. | 0.2 | 128 |
| 21 | Destabilized Adhesion in the Gastric Proliferative Zone and c-Src Kinase Activation Mark the Development of Early Diffuse Gastric Cancer. Cancer Research, 2007, 67, 2480-2489. | 0.4 | 114 |
| 22 | Multiple Gene Expression Classifiers from Different Array Platforms Predict Poor Prognosis of Colorectal Cancer. Clinical Cancer Research, 2007, 13, 498-507. | 3.2 | 114 |
| 23 | E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition. BMC Cancer, 2014, 14, 552. | 1.1 | 108 |
| 24 | E-cadherin downregulation in cancer: fuel on the fire?. Trends in Molecular Medicine, 1999, 5, 172-177. | 2.6 | 104 |
| 25 | Secreted CXCL1 Is a Potential Mediator and Marker of the Tumor Invasion of Bladder Cancer. Clinical Cancer Research, 2008, 14, 2579-2587. | 3.2 | 95 |
| 26 | Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 531.e15-531.e22. | 0.8 | 94 |
| 27 | A gene responsible for a dominant form of neurosensory non-syndromic deafness maps to the NSRD1 recessive deafness gene interval. Human Molecular Genetics, 1994, 3, 2219-2222. | 1.4 | 93 |
| 28 | Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Oncogene, 2002, 21, 8192-8195. | 2.6 | 91 |
| 29 | Prognostic Analysis of E-Cadherin Gene Promoter Hypermethylation in Patients with Surgically Resected, Node-Positive, Diffuse Gastric Cancer. Clinical Cancer Research, 2004, 10, 2784-2789. | 3.2 | 83 |
| 30 | Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. Journal of Urology, 2017, 197, 1419-1426. | 0.2 | 82 |
| 31 | Hereditary diffuse gastric cancer: A manifestation of lost cell polarity. Cancer Science, 2009, 100, 1151-1157. | 1.7 | 78 |
| 32 | Development of a Multiplex RNA Urine Test for the Detection and Stratification of Transitional Cell Carcinoma of the Bladder. Clinical Cancer Research, 2008, 14, 742-749. | 3.2 | 74 |
| 33 | Clinical spectrum and pleiotropic nature ofCDH1germline mutations. Journal of Medical Genetics, 2019, 56, 199-208. | 1.5 | 74 |
| 34 | Novel germlineCDH1mutations in hereditary diffuse gastric cancer families. Human Mutation, 2002, 19, 518-525. | 1.1 | 63 |
| 35 | Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma. Clinical Cancer Research, 2008, 14, 5173-5180. | 3.2 | 62 |
| 36 | A Comparison of Real-Time and Endpoint Cell Viability Assays for Improved Synthetic Lethal Drug Validation. Journal of Biomolecular Screening, 2015, 20, 1286-1293. | 2.6 | 51 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | P21-Activated Kinase 1: A New Molecular Marker for Intravesical Recurrence After Transurethral Resection of Bladder Cancer. Journal of Urology, 2007, 178, 1073-1079. | 0.2 | 44 |
| 38 | Hereditary gastric cancer: whatâ€™s new? Update 2013â€“2018. Familial Cancer, 2019, 18, 363-367. | 0.9 | 44 |
| 39 | Expression of KrÃ¼ppel-like factor 5 in human gastric carcinomas. Journal of Cancer Research and Clinical Oncology, 2007, 134, 163-167. | 1.2 | 42 |
| 40 | The International Testicular Cancer Linkage Consortium: A clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 492-499. | 0.8 | 42 |
| 41 | Epigenetic silencing in nonâ€neoplastic epithelia identifies Eâ€cadherin (CDH1) as a target for chemoprevention of lobular neoplasia. Journal of Pathology, 2009, 218, 265-272. | 2.1 | 41 |
| 42 | Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors. Genes Chromosomes and Cancer, 2008, 47, 247-252. | 1.5 | 37 |
| 43 | A short guide to hereditary diffuse gastric cancer. Hereditary Cancer in Clinical Practice, 2007, 5, 183. | 0.6 | 36 |
| 44 | Hereditary diffuse gastric cancer. Advances in Cancer Research, 2001, 83, 55-65. | 1.9 | 35 |
| 45 | Germline CDH1 mutations are a significant contributor to the high frequency of early-onset diffuse gastric cancer cases in New Zealand MÄori. Familial Cancer, 2019, 18, 83-90. | 0.9 | 33 |
| 46 | Genome-wide methylation analysis identifies a core set of hypermethylated genes in CIMP-H colorectal cancer. BMC Cancer, 2017, 17, 228. | 1.1 | 32 |
| 47 | Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherinâ€“Deficient Cells. Molecular Cancer Therapeutics, 2015, 14, 1213-1223. | 1.9 | 30 |
| 48 | Increased levels of active c-Src distinguish invasive from in situ lobular lesions. Breast Cancer Research, 2009, 11, R45. | 2.2 | 28 |
| 49 | A YAC Contig and an EST Map in the Pericentromeric Region of Chromosome 13 Surrounding the Loci for Neurosensory Nonsyndromic Deafness (DFNB1 and DFNA3) and Limb-Girdle Muscular Dystrophy Type 2C (LGMD2C). Genomics, 1995, 29, 163-169. | 1.3 | 25 |
| 50 | E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function. Gastric Cancer, 2019, 22, 273-286. | 2.7 | 24 |
| 51 | Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells. Cancers, 2019, 11, 1359. | 1.7 | 22 |
| 52 | Cohesin mutations are synthetic lethal with stimulation of WNT signaling. ELife, 2020, 9, . | 2.8 | 22 |
| 53 | N-Terminal E-Cadherin Peptides Act as Decoy Receptors for Listeria monocytogenes. Infection and Immunity, 2003, 71, 1580-1583. | 1.0 | 19 |
| 54 | Comparison of Roche Cell-Free DNA collection Tubes to Streck Cell-Free DNA BCT s for sample stability using healthy volunteers. Practical Laboratory Medicine, 2019, 16, e00125. | 0.6 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Organization and interviral homologies of the coat protein gene of white clover mosaic virus. Virology, 1988, 162, 459-465. | 1.1 | 17 |
| 56 | Mutation and replacement of the 16-kDa protein gene IN RNA-1 of tobacco rattle virus. Virology, 1991, 182, 607-614. | 1.1 | 16 |
| 57 | Risk of stomach cancer in Aotearoa/New Zealand: A MÄori population based case-control study. PLoS ONE, 2017, 12, e0181581. | 1.1 | 15 |
| 58 | A novel diffuse gastric cancer susceptibility variant in E-cadherin (CDH1) intron 2: A case control study in an Italian population. BMC Cancer, 2008, 8, 138. | 1.1 | 13 |
| 59 | Hereditary diffuse gastric cancer and lost cell polarity: a short path to cancer. Future Oncology, 2008, 4, 229-239. | 1.1 | 13 |
| 60 | A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells. Scientific Reports, 2019, 9, 12511. | 1.6 | 13 |
| 61 | Identification of c.1531C>T Pathogenic Variant in the CDH1 Gene as a Novel Germline Mutation of Hereditary Diffuse Gastric Cancer. International Journal of Molecular Sciences, 2019, 20, 4980. | 1.8 | 12 |
| 62 | E-cadherin signal sequence disruption: a novel mechanism underlying hereditary cancer. Molecular Cancer, 2018, 17, 112. | 7.9 | 11 |
| 63 | Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer. Carcinogenesis, 2020, 41, 1507-1517. | 1.3 | 11 |
| 64 | Modelling hereditary diffuse gastric cancer initiation using transgenic mouseâ€derived gastric organoids and singleâ€cell sequencing. Journal of Pathology, 2021, 254, 254-264. | 2.1 | 11 |
| 65 | Oligonucleotide array outperforms SNP array on formalin-fixed paraffin-embedded clinical samples. Cancer Genetics and Cytogenetics, 2010, 198, 1-6. | 1.0 | 10 |
| 66 | E-Cadherin-Deficient Epithelial Cells Are Sensitive to HDAC Inhibitors. Cancers, 2022, 14, 175. | 1.7 | 8 |
| 67 | Genomic characterization of multiple clinical phenotypes of cancer using multivariate linear regression models. Bioinformatics, 2007, 23, 732-738. | 1.8 | 7 |
| 68 | Sequence Characterization of a Newly Identified Human Î±-Tubulin Gene (TUBA2). Genomics, 1998, 47, 125-130. | 1.3 | 6 |
| 69 | Loss of E-Cadherin Leads to Druggable Vulnerabilities in Sphingolipid Metabolism and Vesicle Trafficking. Cancers, 2022, 14, 102. | 1.7 | 6 |
| 70 | Culture, law, ethics, and social implications: Is society ready for advanced. Australasian Medical Journal, 2014, 7, 200-202. | 0.1 | 5 |
| 71 | E-Cadherin-Deficient Cells Are Sensitive to the Multikinase Inhibitor Dasatinib. Cancers, 2022, 14, 1609. | 1.7 | 4 |
| 72 | Discovery of AL-GDa62 as a Potential Synthetic Lethal Lead for the Treatment of Gastric Cancer. Journal of Medicinal Chemistry, 2021, 64, 18114-18142. | 2.9 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | E-cadherin unlikely to be a common ?low penetrance? gene for colorectal cancer. American Journal of Medical Genetics Part A, 1999, 84, 169-171. | 2.4 | 3 |
| 74 | Updated perspective and directions on hereditary diffuse gastric cancer. , 2021, , 217-258. | | 1 |
| 75 | An estimate of limited duration cancer prevalence in New Zealand using 'big' data. New Zealand Medical Journal, 2020, 133, 49-62. | 0.5 | 1 |
| 76 | Gastric Cancer: Inherited Predisposition. , 2002, , 253-258. | | 0 |
| 77 | Molecular Mechanisms of Hereditary Diffuse Gastric Cancer Initiation and Progression. , 2013, , 51-76. | | 0 |
| 78 | Where to from here? Posthumous healthcare data, digital e(lectronic)-mortality and New Zealand's healthcare future. New Zealand Medical Journal, 2017, 130, 64-70. | 0.5 | 0 |